Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
October 15th, 2021
16.8K views
Here, we present a protocol for the purification of MHC class I and class II peptide complexes from mouse and human cell lines providing high-quality immunopeptidomics data. The protocol focuses on sample preparation using commercially available antibodies.
Overview
This protocol outlines a straightforward method for purifying MHC class I and class II peptide complexes from mouse and human cell lines, enabling high-quality immunopeptidomics data. It is designed to be accessible for any laboratory, facilitating research in various areas involving the immune system.
Key Study Components
Area of Science
- Immunology
- Peptide purification
- Immunopeptidomics
Background
- MHC class I and II molecules play crucial roles in immune response.
- Understanding peptide presentation is vital for cancer and autoimmune disease research.
- Current methods for peptide isolation can be complex and resource-intensive.
- This protocol aims to simplify the process for broader accessibility.
Purpose of Study
- To provide a reliable protocol for isolating MHC peptides.
- To enhance the quality of immunopeptidomics data.
- To support research across various fields related to the immune system.
Methods Used
- Activation of Sepharose cyanogen bromide beads.
- Coupling antibodies to beads for peptide isolation.
- Cell lysis and incubation with antibody-coupled beads.
- Desalting and elution of MHC peptides using C-18 columns.
Main Results
- High recovery of MHC peptide complexes confirmed by detection signals.
- Low coefficient of variation indicates reproducibility across biological replicates.
- Protocol allows for effective isolation of peptides for mass spectrometry analysis.
- Demonstrated applicability to various research areas, including cancer and autoimmune diseases.
Conclusions
- The protocol is simple and accessible for any research laboratory.
- It provides a robust method for studying MHC peptide presentation.
- Future applications may enhance understanding of immune responses in health and disease.
Frequently Asked Questions
What types of samples can be used with this protocol?
This protocol can be used with both mouse and human cell lines.
How long does the entire purification process take?
The purification process typically spans over two days, including overnight incubation.
Is prior experience required to perform this protocol?
No, the protocol is designed to be straightforward and accessible for researchers at any level.
What are the main applications of the purified MHC peptides?
Purified MHC peptides can be used for mass spectrometry analysis and to study immune responses.
Can this protocol be adapted for other types of peptides?
While this protocol is optimized for MHC peptides, adaptations may be possible for other peptide types.
What is the significance of using anti-HAL-ABC heavy-chain antibody?
This antibody helps confirm the successful isolation of MHC peptide complexes.
Executive Industry Relevance
Immunopeptidomics enables direct interrogation of antigen presentation, a critical step in vaccine and immunotherapy development. This protocol provides a standardized, accessible method for isolating MHC-associated peptides from murine and human models, supporting target validation and mechanistic de-risking in early discovery. By delivering reproducible peptide profiles, it enhances predictive confidence in lead selection and reduces biological attrition in oncology, virology, and autoimmune disease programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of MHC-restricted epitopes to confirm target relevance in immune-mediated diseases.
- Operational Value: Uses immunoaffinity purification with validated antibodies to isolate native peptide-MHC complexes from physiologically relevant cell lines.
- Predictive Value: Generates quantitative peptide profiles that support epitope prioritization and reduce false positives in target hypothesis testing.
Screening & Assay Development
- Scientific Value: Produces desalted, MS-ready peptide fractions suitable for label-free or targeted mass spectrometry quantification.
- Operational Value: Incorporates bead-binding and elution efficiency checks to ensure assay robustness and inter-run consistency.
- Scalability: Compatible with 100 million cell inputs, enabling batch processing for screening campaigns across multiple conditions.
Translational & Preclinical Research
- Translational Continuity: Bridges in vitro findings to in vivo relevance by isolating peptides from murine models used in disease validation.
- Biomarker Alignment: Identifies naturally processed peptides that can serve as translational biomarkers for immune response monitoring.
- Risk Mitigation: Reduces mechanistic ambiguity in immuno-oncology and autoimmune target selection through direct epitope evidence.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through lead optimization, providing antigen presentation data that informs immunotherapeutic design and preclinical candidate selection.
- Discovery Biology: Supports hypothesis testing by revealing the endogenous peptidome presented by MHC molecules in disease-relevant contexts.
- Screening: Enables standardized preparation of peptide libraries for downstream immune profiling and neoantigen discovery efforts.
- Analytics: Delivers quantitative, MS-compatible outputs that allow comparison of peptide abundance and diversity across experimental groups.
- Translational Research: Connects cellular antigen presentation to preclinical models by isolating peptides from murine systems used in efficacy studies.
- Enterprise Reuse: Establishes a reproducible sample preparation foundation that can be shared across immunology, oncology, and infectious disease teams.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence through direct measurement of the immunopeptidome.
- Operational Value: Standardizes peptide isolation via defined bead coupling, blocking, and elution steps to minimize variability.
- Strategic Value: Informs go/no-go decisions by providing evidence of antigen processing and presentation efficiency.
- Portfolio Impact: Enables risk-adjusted prioritization of immunotherapeutic candidates based on epitope quality and reproducibility.
Implementation Considerations
- Requires expertise in immunology and protein chemistry for antibody selection and bead handling.
- Depends on access to rotators, centrifuges, and C-18 desalting columns for peptide purification.
- Necessitates standardization of antibody coupling and validation across lots to ensure bead-binding efficiency.
- Involves optimization of lysis and incubation conditions for different cell types and tissue sources.
- Limited by input material requirements, necessitating sufficient cell numbers for detectable peptide yields.
Biopharma FAQs
Why is bead-binding efficiency verified before peptide isolation?
Verifying bead-binding efficiency ensures that antibodies are properly covalently attached to the cyanogen bromide-activated beads, which is critical for capturing MHC-peptide complexes during incubation. This step prevents false negatives due to inadequate antibody coupling and supports reproducible immunopeptidome recovery across replicates.
How does overnight incubation at 4°C contribute to MHC peptide isolation?
The 14 to 18-hour incubation at 4°C allows sufficient time for antibody-coupled beads to bind MHC-peptide complexes from the cell lysate under equilibrium conditions. This extended, low-temperature incubation maximizes complex recovery while minimizing nonspecific binding and proteolytic degradation.
What does the elution with 1% TFA achieve in the workflow?
Elution with 1% trifluoroacetic acid (TFA) dissociates MHC-peptide complexes from the antibody-coupled beads while preserving peptide integrity for downstream analysis. This acidic elution step is essential for releasing bound peptides before desalting and mass spectrometry preparation.
Why are replication requirements emphasized for cross-functional collaboration?
Replicate consistency, measured by low coefficient of variation in peptide detection (1.9–11%), ensures that observed immunopeptidome profiles are reliable and not due to technical noise. This reproducibility enables confident data sharing between discovery, translational, and preclinical teams for target validation.
What statistical analysis is needed to assess peptide reproducibility across replicates?
Analysis of peptide detection frequency and coefficient of variation across biological replicates is required to quantify reproducibility, as demonstrated by the reported 39–63% overlap in peptide identity. This statistical evaluation supports data quality assessment before advancing candidates in the discovery pipeline.
